On the public citation graph

A Pulmonary Formulation of l-Dopa Enhances Its Effectiveness in a Rat Model of Parkinson’s Disease

https://doi.org/10.1124/jpet.103.064121
0 signed · 76 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/1531-8257(200005)15:3<459::aid-mds1006>3.0.co;2-3openalex-snapshot
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
inferredcites →https://doi.org/10.1002/ana.410220105openalex-snapshot
Multi‐center study of Parkinson mortality with early versus later dopa treatment
inferredcites →https://doi.org/10.1002/ana.410220415openalex-snapshot
On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
inferredcites →https://doi.org/10.1002/ana.410240116openalex-snapshot
Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism
inferredcites →https://doi.org/10.1002/ana.410240303openalex-snapshot
Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I
inferredcites →https://doi.org/10.1002/ana.410240304openalex-snapshot
Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II
inferredcites →https://doi.org/10.1002/ana.410390504openalex-snapshot
The response to levodopa in parkinson's disease: Imposing pharmacological law and order
inferredcites →https://doi.org/10.1002/cpt1971122part1212openalex-snapshot
Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor
inferredcites →https://doi.org/10.1002/syn.890180403openalex-snapshot
Differential effect of MK 801 and scopolamine on c‐fos expression induced by L‐dopa in the striatum of 6‐hydroxydopamine lesioned rats
inferredcites →https://doi.org/10.1007/978-1-59259-691-1openalex-snapshot
Central Nervous System Diseases
inferredcites →https://doi.org/10.1007/978-1-59259-691-1_8openalex-snapshot
Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism
inferredcites →https://doi.org/10.1007/978-3-7091-6360-3_11openalex-snapshot
Current management of motor fluctuations in patients with advanced Parkinson’s disease treated chronically with levodopa
inferredcites →https://doi.org/10.1016/0006-8993(89)91689-2openalex-snapshot
D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour
inferredcites →https://doi.org/10.1016/0361-9230(96)00027-5openalex-snapshot
Validation of a rodent model of Parkinson's disease: Evidence of a therapeutic window for oral Sinemet
inferredcites →https://doi.org/10.1016/s0140-6736(76)91416-1openalex-snapshot
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY
inferredcites →https://doi.org/10.1016/s0378-5173(02)00349-6openalex-snapshot
In vitro and in vivo dose delivery characteristics of large porous particles for inhalation
inferredcites →https://doi.org/10.1038/19899openalex-snapshot
From entropy to Duino
inferredcites →https://doi.org/10.1038/399a032openalex-snapshot
Prospects for new restorative and neuroprotective treatments in Parkinson's disease
inferredcites →https://doi.org/10.1056/nejm196702162760703openalex-snapshot
Aromatic Amino Acids and Modification of Parkinsonism
inferredcites →https://doi.org/10.1097/00002826-198808000-00007openalex-snapshot
Central Mechanisms and Levodopa Response Fluctuations in Parkinsonʼs Disease
inferredcites →https://doi.org/10.1111/j.1365-201x.1971.tb11000.xopenalex-snapshot
Postsynaptic Supersensitivity after 6‐Hydroxy‐dopamine Induced Degeneration of the Nigro‐striatal Dopamine System
inferredcites →https://doi.org/10.1111/j.1365-2362.1971.tb00637.xopenalex-snapshot
Absorption and Metabolism of L‐Dopa by the Human Stomach
inferredcites →https://doi.org/10.1126/science.2147780openalex-snapshot
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
inferredcites →https://doi.org/10.1126/science.276.5320.1868openalex-snapshot
Large Porous Particles for Pulmonary Drug Delivery
inferredcites →https://doi.org/10.1212/wnl.43.9.1698openalex-snapshot
Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations
inferredcites →https://doi.org/10.1212/wnl.46.4.1051openalex-snapshot
Gastric emptying in Parkinson's disease
inferredcites →https://doi.org/10.1523/jneurosci.12-10-03729.1992openalex-snapshot
D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease
inferredcites →https://doi.org/10.2165/00003088-198713030-00002openalex-snapshot
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4661733openalex-extracted
Taking Advantages of Blood–Brain Barrier to Optimize Delivery of Drugs in Central Neurological Conditions
inferred← citeshttps://doi.org/10.1002/9780470571224.pse357openalex-snapshot
Aerosol Drug Delivery
inferred← citeshttps://doi.org/10.1007/s11033-023-08968-3openalex-snapshot
Current non-invasive strategies for brain drug delivery: overcoming blood–brain barrier transport
inferred← citeshttps://doi.org/10.1007/s11095-007-9475-1openalex-snapshot
Pharmaceutical Particle Engineering via Spray Drying
inferred← citeshttps://doi.org/10.1007/s11095-022-03363-2openalex-snapshot
Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics
inferred← citeshttps://doi.org/10.1007/s40005-021-00529-9openalex-snapshot
Surface modification strategies for high-dose dry powder inhalers
inferred← citeshttps://doi.org/10.1016/b978-0-443-07941-2.50012-7openalex-snapshot
Experimental Models and New, Emerging Therapies for Parkinson Disease
inferred← citeshttps://doi.org/10.1016/j.apt.2020.03.028openalex-snapshot
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson’s disease through intranasal and pulmonary delivery
inferred← citeshttps://doi.org/10.1016/j.ejpb.2014.06.014openalex-snapshot
In vitro evaluation of the DP-4M PennCentury™ insufflator
inferred← citeshttps://doi.org/10.1016/j.ejpb.2015.10.003openalex-snapshot
A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods
inferred← citeshttps://doi.org/10.1016/j.ejps.2021.106008openalex-snapshot
Engineering of levodopa inhalable microparticles in combination with leucine and dipalmitoylphosphatidylcholine by spray drying technique
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2024.05.008openalex-snapshot
Dopamine and its precursor levodopa inactivate SARS-CoV-2 main protease by forming a quinoprotein
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2009.07.026openalex-snapshot
Levodopa delivery systems for the treatment of Parkinson's disease: An overview
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2012.05.013openalex-snapshot
Pulmonary delivery of dry powders to rats: Tolerability limits of an intra-tracheal administration model
inferred← citeshttps://doi.org/10.1016/j.nbd.2012.04.004openalex-snapshot
Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest
inferred← citeshttps://doi.org/10.1016/j.pneurobio.2006.11.009openalex-snapshot
Advances in the treatment of Parkinson's disease
inferred← citeshttps://doi.org/10.1038/npjparkd.2016.23openalex-snapshot
Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
inferred← citeshttps://doi.org/10.1038/s41467-017-01419-1openalex-snapshot
In vivo neurochemical measurements in cerebral tissues using a droplet-based monitoring system
inferred← citeshttps://doi.org/10.1038/s41578-025-00841-yopenalex-snapshot
Inhalable materials and biologics for lung defence and drug delivery
inferred← citeshttps://doi.org/10.1080/14656566.2021.1895748openalex-snapshot
An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson’s disease
inferred← citeshttps://doi.org/10.1080/14737175.2019.1621748openalex-snapshot
CVT-301 for the treatment of Parkinson’s disease
inferred← citeshttps://doi.org/10.1080/17425247.2021.1960820openalex-snapshot
A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson’s disease
inferred← citeshttps://doi.org/10.1080/17425255.2018.1550483openalex-snapshot
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease
inferred← citeshttps://doi.org/10.1080/17512433.2020.1724535openalex-snapshot
Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson’s disease
inferred← citeshttps://doi.org/10.1097/wnf.0000000000000540openalex-snapshot
The Clinical Development of Levodopa Inhalation Powder
inferred← citeshttps://doi.org/10.1126/scitranslmed.aad8858openalex-snapshot
Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease
inferred← citeshttps://doi.org/10.13040/ijpsr.0975-8232.10(4).2004-11openalex-snapshot
inferred← citeshttps://doi.org/10.1371/journal.pone.0132714openalex-snapshot
Can Patients with Parkinson’s Disease Use Dry Powder Inhalers during Off Periods?
inferred← citeshttps://doi.org/10.1517/14656561003598919openalex-snapshot
Levodopa in Parkinson's disease: from the past to the future
inferred← citeshttps://doi.org/10.1517/17425240902870405openalex-snapshot
New drug delivery strategies for improved Parkinson's disease therapy
inferred← citeshttps://doi.org/10.1517/17425240903241788openalex-snapshot
Preclinical models for pulmonary drug delivery
inferred← citeshttps://doi.org/10.1517/17425240903483166openalex-snapshot
Levodopa delivery systems: advancements in delivery of the gold standard
inferred← citeshttps://doi.org/10.1517/17425247.2.6.1059openalex-snapshot
Advances in the delivery of treatments for Parkinson’s disease
inferred← citeshttps://doi.org/10.1517/17425247.2011.556616openalex-snapshot
New non-oral drug delivery systems for Parkinson's disease treatment
inferred← citeshttps://doi.org/10.2147/ndt.s147633openalex-snapshot
Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
inferred← citeshttps://doi.org/10.2165/00003088-200645020-00001openalex-snapshot
Pharmacokinetic Optimisation in the Treatment of Parkinson???s Disease
inferred← citeshttps://doi.org/10.2174/1381612821666150820111134openalex-snapshot
Powder Production and Particle Engineering for Dry Powder Inhaler Formulations
inferred← citeshttps://doi.org/10.2174/1567201818666210331121803openalex-snapshot
Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson’s Disease
inferred← citeshttps://doi.org/10.2174/187152408785699613openalex-snapshot
Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
inferred← citeshttps://doi.org/10.22456/2527-2616.150700openalex-snapshot
Novel levodopa microparticles for pulmonary delivery and in vivo respiratory tract toxicity study
inferred← citeshttps://doi.org/10.32657/10356/158934openalex-snapshot
Development of Levodopa-loaded inhalable dry powders for treatment of Parkinson's disease via the pulmonary system
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1178448openalex-snapshot
C-reactive protein as the biomarker of choice to monitor the effects of exercise on inflammation in Parkinson’s disease
inferred← citeshttps://doi.org/10.3389/fnagi.2025.1692592openalex-snapshot
Drug discovery and development for Parkinson’s disease: are preclinical models good enough?
inferred← citeshttps://doi.org/10.3390/pharmaceutics14050931openalex-snapshot
3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
inferred← citeshttps://doi.org/10.4155/tde.11.90openalex-snapshot
Pulmonary Delivery of Therapeutic Compounds for Treating CNS Disorders
inferred← citeshttps://doi.org/10.5582/ddt.2012.v6.3.123openalex-snapshot
Improved treatment of nicotine addiction and emerging pulmonary drug delivery
inferred← citeshttps://doi.org/10.5607/en.2014.23.3.246openalex-snapshot
Increasing the Effciency of Parkinson’s Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System
inferred← citeshttps://doi.org/10.70675/03166a20zd23bz4ca1z8706z5d3f89b3c5ddopenalex-snapshot
Particulate systems for lung delivery of pyrazinamide for tuberculosis treatment
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.